In March 2022,[177Lu] Lu-PSMA-617 (PluvictoTM) was approved by the FDA for the
treatment of prostate cancer patients. Until now, the approval has been limited to patients …

Currently, the findings of imaging procedures used for detection or staging of prostate
cancer depend on morphology of lymph nodes or bone metabolism and do not always meet …

Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer.
Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA …

177Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy
(RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). Initiated by …

The aim of this guideline is to provide standards for the recommendation, performance,
interpretation and reporting of 68 Ga-PSMA PET/CT for prostate cancer imaging. These …

Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy
of metastasized castration-resistant prostate cancer (mCRPC). Besides high affinity and long …

Radiometals possess an exceptional breadth of decay properties and have been applied to
medicine with great success for several decades. The majority of current clinical use …

The aim of this study was to develop a treatment protocol for 225Ac-PSMA-617 α-radiation
therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with …

Background A remarkable therapeutic efficacy has been demonstrated with 225 Ac-prostate-
specific membrane antigen (PSMA)-617 in heavily pre-treated metastatic castration-resistant …

Positron emission tomography (PET) constitutes a functional imaging technique that is
harnessed to probe biological processes in vivo. PET imaging has been used to diagnose …